TITLE:
Adjuvants Derived from Neisseria meningitidis Serogroup B Induce a Cross Reactive Response against Neisseria gonorrhoeae in Mice
AUTHORS:
Laura M. Reyes, Miriam Lastre, Maribel Cuello, Osmir Cabrera, Yusnaby Borrego, Raúl Ramos Pupo, Steve Black, Oliver Pérez
KEYWORDS:
N. meningitidis, N. gonorrhoeae, Vaccine, Cross Reactivity
JOURNAL NAME:
Open Journal of Immunology,
Vol.10 No.3,
September
29,
2020
ABSTRACT: Introduction: Neisseria is a large genus of
bacteria that colonize mucosal surfaces. Of the 11 species that colonize
humans, only two are pathogens, N.
meningitidis and N. gonorrhoeae.
Both are obligate human pathogens; the last is causal agent of gonorrhea disease. Although curable with
timely antibiotic treatment, an annual incidence of more than 62 million cases
is estimated by the World Health Organization and there are no successful
vaccines available. In contrast, several prophylactic vaccine options for Neisseria meningitidis meningitis do
exist. Of note, there is trace of cross parenteral response induced between N. meningitidis and N. gonorrhoeae, and Proteoliposome (PL, also named outer membrane vesicles, OMV) vaccine has shown high
impact on this response. Objective: To determine effect of VAMENGOC-BC? and
its derivates (AFPL1 and AFCo1) at mucosal and systemic level and possible
cross response against Neisseria gonhorroeae in Balb/c and C57Bl/6 mice. Methods: We evaluated cross response against N.
gonorrhoeae in mouse serum IgG and saliva IgA after mucosal immunization
with VA-MENGOC-BC or its derivatives (AF, Adjuvant Finlay PL1 or AFCo
(cochleate) 1). Results: Immunizations with AFPL1 or AFCo1 induce anti N. gonorrhoeae at saliva IgA and serum IgG
responses similar to VA-MENGOC-BC? vaccine. Conclusions: Such data confirms a new
possible window of prime-boost vaccination strategy against gonorrhea and
extends our knowledge regarding the effect of PL vaccines on cross responses.